Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough
Femme et Homme Max 99 ans
Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough
MAJ Il y a 4 ans
A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus – The ENDURE Study
To compare throughout the study the efficacy of PEG-Intron® monotherapy versus standard supportive care, using the time to the first occurrence of any one of the following clinical events (death, live...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough
MAJ Il y a 4 ans
Comparison of Three Regimens of PEG-Intron plus Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients
To examine the effect of peg-Intron dose by comparing the "standard" regimen, peg-Intron 1.5 mcg/kg qW sc plus ribavirin 800-1200 mg daily, to a lower dose regimen, peg-Intron 1.0 mcg/kg qW sc plus ri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough
MAJ Il y a 4 ans
Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys
The objective of this study is to determine the proportion of chronic hepatitis C genotype 1 subjects who did not respond to previous treatment with Pegasys 180µg QW plus ribavirin, that will achieve ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations